Sign up USA
Proactive Investors - Run By Investors For Investors

Akers Biosciences surges after beefing up commercial team

The two recruits have skill sets that are highly relevant to Akers's commercial strategy
Akers Biosciences surges after beefing up commercial team
Akers develops and supplies rapid screening and testing products

Akers Biosciences (LON:AKR, NASDAQ:AKER), a developer of health information technologies, has strengthened its commercial team with two sales and marketing recruits.

Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.

Carrara has over 25 years' experience in the clinical diagnostics arena, particularly within sales, marketing and global operations. He joins Akers Bio from Quest Diagnostics where he was the senior director of Strategic Accounts, leading a team of directors responsible for developing and implementing strategic relationships within the acute care market.

Saporito has a track record of building and leading high-performance businesses in the medical device and clinical diagnostics arenas for two decades. Prior to joining Akers Bio, he held the role of strategic account executive with The Midmark Corporation, where he was responsible for driving new business through group purchasing organisations, integrated health systems and distribution.

“Their skill sets are highly relevant to our commercial strategy for growing product sales over the coming years and we are very excited to have them on board," said Raymond Akers, co-founder and executive chairman of the dual-listed medical screening and testing products developer.

Chief executive John Gormally said: "Having worked with both Douglas and Tony at Becton Dickinson, I have direct experience of their first class abilities to execute highly profitable sales strategies.

"Douglas will be instrumental in building an evidence-based outcome value proposition marketing strategy, particularly to support the growth of Akers Bio's flagship test for heparin-induced thrombocytopenia. Tony will lead the channel management strategy for Akers Bio in the US as we develop highly engaged, integrated business plans with our customers and distribution partners that enhance mutual gains in efficiency, productivity and profitability," he said.

Shares in Akers surged 7.7% to 105p on news of the announcements.

View full AKR profile View Profile

Akers Biosciences, Inc. Timeline

Related Articles

the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
ventripoint_device.png
June 21 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use